Al₈(OH)₁₆(C₁₂H₁₄O₃₅S₈) [Al(OH)₃]_x [H₂O]_y  

Sucralfate is the basic aluminium salt of sucrose octasulfate (SOS). The therapeutic effect of Sucralfate in gastric complaints is based on an increase in the protective mechanisms of the mucous membranes in the stomach and duodenum against exogenous and endogenous aggressors.

The cytoprotective action of Sucralfate includes the neutralization of acid, the selective formation of a protective layer over eroded surface areas, specific protection of lesions and adsorption of pepsin and bile acids, resulting in inhibition of peptic activity.
 

Sucralfate Powder S 215, S 225 and S 235

Sucralfate S 215 powder is suitable for use in tablet formulations. Sucralfate S225 is a milled powder ideal for use in soft tablet and candy formulations or for powder mixtures intended for resuspending (powder sachets). Sucralfate S 235 is available for direct compressible tablet formulations.

Type	Assay Al	Assay SOS	Density (tapped)	d50	Pharmacopoeia
S 215	15,5 - 18,5 [%]  16,5 - 18,5 [%]	30,0 - 38,0 [%]  30,0 - 36,0 [%]	0,65 - 0,85 [g/ml]	30 - 40 [µm]	USP  PhEur
S 225	15,5 - 18,5 [%]  16,5 - 18,5 [%]	30,0 - 38,0 [%]  30,0 - 36,0 [%]	0,30 - 0,48 [g/ml]	~ 4 [µm]	USP  PhEur
S 235	15,5 - 18,5 [%]  16,5 - 18,5 [%]	30,0 - 38,0 [%]  30,0 - 36,0 [%]	0,6 - 0,8 [g/ml]	90 - 130    [µm]	USP  PhEur

Sucralfate Suspension S 611

Sucralfate S611 is a suspension with an active content of 30% Sucralfate. It is ideal for use in liquid antacid formulations.

Type	Assay	Assay SOS	d50	Pharmacopoeia
S611	4,7 - 6,0 [%]	8,3 - 13,4 [%]	4 - 6 µm	USP